Malecare Advanced Prostate Cancer Teleconference
Join us for a conversation about treating advanced stage prostate cancer, with James M. McKiernan, M.D. and Joel Nowak, M.A., M.S.W. […]
Salvage Radiotherapy after High-Intensity Focused Ultrasound (HIFU) for Recurrent Localized Prostate Cancer
HIFU has been a common primary prostate cancer treatment in Europe for quite a while. Currently, in the United States, there are a number of clinical trial sites evaluating HIFU as a primary treatment. Like all other primary treatments there is a significant failure rate causing men to move on to salvage therapy. In Europe [...]
Phase II Study of Nitric Oxide for Men with Increasing PSAs After Primary Treatment for Prostate Cancer
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]
Can B7-H3 Expression Serve as a Biomarker of Biochemical Recurrence after Salvage Radiation Therapy for Recurrent Prostate Cancer?
Current knowledge makes it very difficult to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa). We are also lacking in novel targets for adjuvant therapies. At the College of Medicine, Mayo Clinic Florida, Jacksonville, FL., researchers evaluated the association of B7-H3 expression in primary PCa [...]
Docetaxel (Chemotherapy) Re-Treatment – Can It Work Again?
A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy. The researchers evaluated 45 men who had initially responded [...]
Baseline PSA Predicts Risk of Death from Prostate Cancer
The common question when we are diagnosed with prostate cancer is how long do I have to live? The exact same question is asked again when we discover that we have had a prostate cancer recurrence. Times have changed and so has our potential life span. In the late 1980s and early 1990s men diagnosed [...]
Finasteride Extends PSA Doubling Time & Reduces the Rate of PSA Increase
Finasteride, which remains a controversial drug in the treatment of men with advanced prostate cancer, prolongs the time of off-treatment in men with advanced prostate cancer when they are using intermittent androgen suppression therapy (IAD). One of the questions not yet understood is whether this results from a true increase in prostate-specific antigen (PSA) doubling [...]
The Long-Term Survival of Patients with Metastatic Prostate Cancer
Mike Scott who writes the THE “NEW” PROSTATE CANCER INFOLINK today published an excellent summary/discussion about survival time for men with metastatic prostate cancer. He presents a synopsis about anticipated survival going back to the late 1980s and brings the conversation up to our current condition. He reminds us that our next big step will [...]
Phase II trial Combining Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer
Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]
Statin Drugs Lower the Risk of a Recurrence, but Not Without Risk
Statin drugs improve blood cholesterol levels, but they also cause problems. They also seem to lower the risk of prostate cancer recurrences post surgery by as much as 30% according to researchers at Duke University. These findings are published in the journal Cancer. Stephen Freedland, M.D., a member of the Duke Prostate Center and the [...]